Naturally Splendid Responds to Health Canada’s Information Request Notice

Vancouver, British Columbia – TheNewswire – October 16, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) has responded through their joint venture Plasm Pharmaceutical (“Plasm”) to Health Canada’s Information Request Notice (“IRN”). The questions as posed by Health Canada are considered a formality as Plasm Pharmaceutical, continues to prepare for aContinue reading “Naturally Splendid Responds to Health Canada’s Information Request Notice”

Health Canada Requests Protocol Details of COVID-19 Phase 2 Clinical Trial

– TheNewswire – August 10, 2020 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) advises that subsequent to Heath Canada issuing a No Objection Letter, they have requested specific protocol details regarding the Clinical Trial Application for CavaltinibTM, the target drug of the proposed joint venture with Biologic Pharmaceutical Research, before the trial may commence.Continue reading “Health Canada Requests Protocol Details of COVID-19 Phase 2 Clinical Trial”

Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial

Vancouver, British Columbia – TheNewswire – June 1, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to provide the following progress update for a Phase 2 clinical trial treatment for COVID 19. The Company is now awaiting notification by Health Canada to proceed to the Phase 2 clinical trial stage,Continue reading “Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial”